Figure 2
From: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
PI3K and MEK inhibitors and their combinations in cancer cell lines. The cells were exposed to specific treatments for 72 h and analyzed with the MTS cytotoxicity assay. The single inhibitor treatments are represented with dashed lines and their combinations with continuous lines. (A) NSCLC cell lines. The cell lines are placed in four groups based on their oncogenic genotype (K-Ras mutant, EGFR mutant, ALK translocated, and triple wild type). (B) Breast cancer line MDA-MB231 and colorectal cancer line HCT116, known from the previous literature to be sensitive to dual PI3K and MEK inhibition. Error bars show SD.